

### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# Single Technology Appraisal


# Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981

## **Final Stakeholder List**

Consultees	Commentators (no right to submit or appeal)
Company	General
Sanofi (isatuximab)	All Wales Therapeutics and Toxicology     Centre
<ul> <li>Patient/carer groups</li> <li>African Caribbean Leukaemia Trust</li> <li>Anthony Nolan</li> <li>Black Health Agency for Equality</li> <li>Blood Cancer UK</li> <li>Cancer Black Care</li> <li>Cancer Equality</li> <li>Cancer52</li> <li>DKMS</li> <li>Helen Rollason Cancer Charity</li> <li>Independent Cancer Patients Voice</li> <li>Kevin Karawa Leukaemia Trust</li> <li>Leukaemia Cancer Society</li> <li>Leukaemia Care</li> </ul>	<ul> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> </ul>
<ul> <li>Leukaemia UK</li> <li>Macmillan Cancer Support</li> <li>Maggie's Centres</li> <li>Marie Curie</li> </ul>	<ul><li>Welsh Government</li><li>Welsh Health Specialised Services Committee</li></ul>
<ul> <li>Myeloma UK</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Tenovus Cancer Care</li> </ul>	<ul> <li>Possible comparator companies</li> <li>Accord Healthcare (bortezomib, lenalidomide)</li> <li>Advanz Pharma (dexamethasone, lenalidomide)</li> </ul>
<ul> <li>Healthcare professional groups</li> <li>Association of Cancer Physicians</li> <li>British Blood Transfusion Society</li> <li>British Geriatrics Society</li> <li>British Institute of Radiology</li> <li>British Oncology Pharmacy Association</li> </ul>	<ul> <li>Amarox (lenalidomide)</li> <li>Aspen (dexamethasone)</li> <li>Aspire Pharma (bortezomib, dexamethasone)</li> <li>Aurobindo Pharma (bortezomib)</li> <li>Baxter Healthcare (cyclophosphamide)</li> <li>Biocon Pharma (lenalidomide)</li> </ul>

Provisional stakeholder list for evaluation of isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981


Issue date: August 2024



Consultees	Commentators (no right to submit or appeal)
<ul> <li>British Psychosocial Oncology Society</li> <li>British Society for Haematology</li> <li>British Society of Interventional Radiology</li> <li>British Transplantation Society</li> <li>Cancer Research UK</li> <li>NHS Blood and Transplant</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Myeloma Society</li> <li>UK Oncology Nursing Society</li> </ul> Others <ul> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	<ul> <li>Biotech Pharma (bortezomib)</li> <li>Bristol-Myers Squibb (lenalidomide)</li> <li>Dr Reddy's Laboratories (bortezomib)</li> <li>Fresenius Kabi (bortezomib)</li> <li>Hameln Pharmaceuticals (dexamethasone)</li> <li>Glenmark Pharmaceuticals (dexamethasone)</li> <li>Hospira (dexamethasone)</li> <li>J&amp;J Innovative Medicine (bortezomib, daratumumab)</li> <li>Kent Pharma (bortezomib)</li> <li>Krka UK (dexamethasone)</li> <li>Martindale Pharma (dexamethasone)</li> <li>Medac gmBH (bortezomib)</li> <li>MSN Laboratories Europe (bortezomib)</li> <li>Mylan (bortezomib, lenalidomide)</li> <li>Pfizer (bortezomib)</li> <li>Piramal Critical Care (lenalidomide)</li> <li>Rosemont Pharmaceuticals (dexamethasone)</li> <li>Sandoz (bortezomib, cyclophosphamide)</li> <li>Sun Pharmaceuticals (bortezomib, lenalidomide)</li> <li>Synchrony Pharma (dexamethasone)</li> <li>Teva UK (dexamethasone, lenalidomide)</li> <li>Thornton &amp; Ross (bortezomib, lenalidomide)</li> <li>Tillomed Laboratories (bortezomib)</li> <li>Torrent Pharma (lenalidomide)</li> <li>Viatris UK Healthcare (bortezomib, lenalidomide)</li> <li>Zentiva (lenalidomide)</li> <li>Zentiva (lenalidomide)</li> <li>Relevant research groups</li> <li>Cochrane Haematological Malignancies Group</li> <li>Genomics England</li> <li>Institute of Cancer Research</li> <li>Leukaemia Busters</li> <li>MRC Clinical Trials Unit</li> </ul>

Provisional stakeholder list for evaluation of isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981

Issue date: August 2024



Consultees	Commentators (no right to submit or appeal)
	<ul> <li>National Institute for Health Research</li> <li>Associated Public Health groups</li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### **Commentators**

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.